Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

|Videos|July 16, 2021

Urology Times Journal

Vol 49 No 07
Volume 49
Issue 07

Urology Malpractice: What qualities make an expert witness successful?

Author(s)Urology Times staff

“The side that can take…complex issues and make them simple…is likely going to be the side that wins in a case,” says Kenton H. Steele, Esq.

In this video, Kenton H. Steele, Esq, explains what is required for an expert witness to be successful in a medical malpractice case. Steele is an attorney in the Columbus, Ohio office of Reminger Co., LPA and specializes in malpractice defense and insurance litigation.

Articles in this issue

over 4 years ago

Article

Urology Times Money Matters: Alternative Investments

over 4 years ago

Article

PSMA, VISION, and the Will Rogers phenomenon

over 4 years ago

Article

ASCO 2021 Recap: What urologists need to know

over 4 years ago

Article

Questionnaires are not counted as tests under new E/M coding guidelines

over 4 years ago

Article

Hyperoxaluria: What is the urologist’s role in diagnosis and treatment?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Arvin George, MD, highlights VAPOR 2 trial of thermal water therapy for prostate cancer

ByArvin George, MD

December 8th 2025

How to prioritize among novel treatment options in NMIBC

BySiamak Daneshmand, MD

December 8th 2025

Mark Tyson, MD shares promising BOND-003 results in papillary NMIBC

ByMark D. Tyson, II, M.D., M.P.H.

December 7th 2025

Choosing salvage therapy after prostate cancer focal ablation

ByKelly L. Stratton, MD, FACS

December 6th 2025

CAPTAIN trial highlights early advantages of TULSA vs prostatectomy

ByGeoffrey A. Sonn, MD

December 6th 2025

Latest CME

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Arizona

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Arizona

Surabhi Amar, MD, MHA, MBBS; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Scott T. Tagawa, MD, MS, FACP, FASCO; Kate Baxstrom, MD

DSUI Urology on the Beach

In-Person Event

DSUI Urology on the Beach

January 16-18, 2026

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Aaron D. Berger, MD

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Jason M. Hafron, MD

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Stacy Loeb, MD, MSc, PhD (Hon)

Trending on Urology Times

Mark Tyson, MD shares promising BOND-003 results in papillary NMIBC

CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC

Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC

Choosing salvage therapy after prostate cancer focal ablation

SYNC-T demonstrates high bone metastasis resolution in phase 1 cohort

© 2025 MJH Life Sciences^®

All rights reserved.